Goldman Sachs
TARS icon

Goldman Sachs’s Tarsus Pharmaceuticals TARS Stock Holding History

Goldman Sachs’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.8M Buy
439,626
+60,922
+16% +$4.26M ﹤0.01% 2029
2025
Q4 		$31M Buy
378,704
+37,692
+11% +$2.81M ﹤0.01% 1945
2025
Q3 		$20.3M Sell
341,012
-56,982
-14% -$2.81M ﹤0.01% 2255
2025
Q2 		$16.1M Buy
397,994
+96,484
+32% +$4.34M ﹤0.01% 2325
2025
Q1 		$15.5M Sell
301,510
-17,220
-5% -$851K ﹤0.01% 2278
2024
Q4 		$17.6M Buy
318,730
+49,955
+19% +$2.27M ﹤0.01% 2253
2024
Q3 		$8.84M Buy
268,775
+63,224
+31% +$1.78M ﹤0.01% 2844
2024
Q2 		$5.59M Buy
205,551
+1,821
+0.9% +$61.2K ﹤0.01% 3050
2024
Q1 		$7.41M Sell
203,730
-33,709
-14% -$991K ﹤0.01% 2755
2023
Q4 		$4.81M Buy
237,439
+137,377
+137% +$2.29M ﹤0.01% 3192
2023
Q3 		$1.78M Buy
100,062
+23,110
+30% +$409K ﹤0.01% 3857
2023
Q2 		$1.39M Buy
76,952
+48,387
+169% +$769K ﹤0.01% 4126
2023
Q1 		$359K Sell
28,565
-27,103
-49% -$396K ﹤0.01% 5015
2022
Q4 		$816K Sell
55,668
-53,060
-49% -$878K ﹤0.01% 4561
2022
Q3 		$1.86M Buy
108,728
+10,018
+10% +$159K ﹤0.01% 4041
2022
Q2 		$1.44M Buy
98,710
+70,454
+249% +$1.06M ﹤0.01% 4328
2022
Q1 		$475K Buy
28,256
+153
+0.5% +$2.84K ﹤0.01% 5349
2021
Q4 		$632K Buy
28,103
+1,623
+6% +$42.2K ﹤0.01% 5208
2021
Q3 		$571K Sell
26,480
-400
-1% -$9.9K ﹤0.01% 5116
2021
Q2 		$779K Sell
26,880
-2,114
-7% -$66K ﹤0.01% 4944
2021
Q1 		$934K Buy
+28,994
New +$1.07M ﹤0.01% 4670

Other funds holding TARS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs's TARS Position: Q1 2026 in Review

Goldman Sachs increased its Tarsus Pharmaceuticals (TARS) stake by 16% in Q1 2026, buying an estimated $4.26M and bringing the position to 439,626 shares worth $30.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2029.

Goldman Sachs first reported a position in TARS in Q1 2021 and has held it in 21 quarters since. The position peaked at $31M in Q4 2025. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

  • Goldman Sachs held 439,626 shares of Tarsus Pharmaceuticals worth $30.8M as of Q1 2026.
  • Goldman Sachs bought 60,922 Tarsus Pharmaceuticals shares in Q1 2026, an estimated $4.26M.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2029 holding.
  • Goldman Sachs first reported a position in Tarsus Pharmaceuticals in Q1 2021 and has held it in 21 quarters since.
  • Goldman Sachs's Tarsus Pharmaceuticals position peaked at $31M in Q4 2025.
  • 253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.